Updated October 2026

Dr. John E. Ervin, MD

Kansas City, MO
Rheumatologist

NPI1376565549

Part D claims, 2019: 11
Publications: 19
Clinical trials: 12
Industry payments: $9,671
Affiliated sites: 1

Practice address: 1010 Carondelet Dr Suite 426 Suite 426, Kansas City, MO 64114
Practice phone: Call (816) 943-1292
Professional email: Get professional email
Personal email: Get personal email
Mobile number: Get mobile number
Social profiles

Primary practice

AMR Clinical Kansas City

Physician office · Kansas City, Missouri

Find Dr. Ervin's professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. John E. Ervin is a rheumatologist in Kansas City, Missouri

Dr. Ervin practices at AMR Clinical Kansas City in Kansas City, Missouri.

Dr. Ervin's NPI, 1376565549, was assigned on July 24, 2006. Dr. Ervin holds Missouri license R7363.

NPI and contact details

NPI: 1376565549NPI Registry (opens in a new tab)
NPI enumeration date: July 24, 2006
NPI status: Active
Practice phone: (816) 943-1292
Professional email: Get email
Personal email: Get email
Mobile number: Get number

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Affiliation Data

Dr. John E. Ervin practices at AMR Clinical Kansas City in Kansas City, Missouri

Dr. Ervin's primary practice is AMR Clinical Kansas City, at 1010 Carondelet Dr Suite 426 Suite 426, Kansas City, MO 64114. The practice phone is (816) 943-1292.

AMR Clinical Kansas City
1010 Carondelet Dr Suite 426 Suite 426, Kansas City, MO 64114Phone(816) 943-1292

Source: Dmand AI Affiliation Data

Dr. John E. Ervin is affiliated with 1 site of care

Dr. Ervin's primary practice is AMR Clinical Kansas City in Kansas City, Missouri.

AMR Clinical Kansas CityPhysician office · Kansas City, MissouriPrimary

Source: Dmand AI Affiliation Data

Dmand AI tracks the EHR system at Dr. John E. Ervin's practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ervin practices. Vendor and product names are available with a free account.

EHR by site
Site	EHR vendor and product
AMR Clinical Kansas City	Available with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every site where Dr. Ervin practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.

Try for free Book a meeting

Dr. John E. Ervin is one of 136 rheumatologists in Missouri

Rheumatology is Dr. Ervin's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Ervin is licensed in Missouri.

Specialties and state licenses

Rheumatology, MissouriPrimaryLicense R7363 · taxonomy 207RR0500X

Rheumatologists near Dr. Ervin

Counts of rheumatologists with a Dmand AI profile, by place and practice. Each opens the list.

136rheumatologists in Missouri 19rheumatologists in Kansas City

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. John E. Ervin wrote 11 Medicare Part D claims in 2019

In 2019, Dr. Ervin wrote 11 Medicare Part D claims. They cover 1 drug, with $101 in total drug cost. In 2016, CMS named 12 claims across 1 drug.

Part D claims, 201911

Drugs named by CMS1

Total drug cost$101

Dr. Ervin's most prescribed drugs by claims, 2019

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Part D claims for drugs CMS names, 2016 to 2019

2016
2019

Claims for drugs CMS names: 2016: 122019: 118%

Drugs named by CMS: 1 in 2019, 1 in 2016.

See all prescribing by Dr. Ervin

Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026

For MedTech and pharma teams

Find rheumatologists like Dr. Ervin by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Try for free Book a meeting

Dr. John E. Ervin has 19 publications on record

Dmand AI links 19 papers to Dr. Ervin, published from 2011 to 2024. 2013 was the busiest year, with 2. The most frequent topics are Antibodies, Viral, Double-Blind Method and Immunogenicity, Vaccine. Dr. Ervin has published most often in J Infect Dis. Dr. Ervin's most frequent co-authors are Ann R. Falsey, MD, Alan J. Kivitz, MD and Seth Mitchell Lieberman, MD.

Papers19

Years published2011 to 2024

Dr. Ervin's papers by year, 2013 to 2024

Topics Dr. Ervin writes about most

Antibodies, Viral
Double-Blind Method
Immunogenicity, Vaccine
Antibodies, Neutralizing
Osteoarthritis, Knee
Influenza Vaccines
Respiratory Syncytial Virus, Human
Respiratory Syncytial Virus Infections

Dr. Ervin's most frequent co-authors

Recent publications by Dr. Ervin

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity (opens in a new tab)

Hum Vaccin ImmunotherOctober 2024Dr. Ervin and 15 co-authors

Antibodies, NeutralizingAntibodies, ViralCD8-Positive T-Lymphocytes

Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease (opens in a new tab)

VaccineApril 2023Dr. Ervin and 12 co-authors

EndoglinHepatitis BHepatitis B Antibodies

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study (opens in a new tab)

PLoS Negl Trop DisMarch 2023Dr. Ervin and 9 co-authors

Antibodies, ViralDengueDengue Vaccines

Author Correction: Anthropogenic modification of forests means only 40% of remaining forests have high ecosystem integrity (opens in a new tab)

Nat CommunJanuary 2021Dr. Ervin and 47 co-authors

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial (opens in a new tab)

EClinicalMedicineDecember 2020Dr. Ervin and 37 co-authors

See all 19 publications and co-authors

See who Dr. Ervin researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Ervin works with, so you can find a warm path to the right rheumatologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. John E. Ervin has worked on 12 clinical trials

Dmand AI links Dr. Ervin to 12 clinical trials, 4 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Rheumatic Diseases, Arthritis, Rheumatoid and Fibromyalgia. GlaxoSmithKline sponsors the most, 3. Open Payments lists research payments to Dr. Ervin that name 2 trials.

Clinical trials with Dr. Ervin by phase

NonePhase 1: no trials
1Phase 1/2: 1 trial
1Phase 2: 1 trial
1Phase 2/3: 1 trial
4Phase 3: 4 trials
NonePhase 4: no trials

Conditions in Dr. Ervin's trials

Rheumatic Diseases
Arthritis, Rheumatoid
Fibromyalgia
Pneumovirus Infections
Muscular Diseases

Investigators on the most trials with Dr. Ervin

Recent clinical trials with Dr. Ervin

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above (opens in a new tab)

CompletedPhase 3NCT04886596 · Started October 8, 2024 · GlaxoSmithKline

Pneumovirus InfectionsRespiratory Syncytial Virus InfectionsRSVPreF3 OA vaccine

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache (opens in a new tab)

CompletedPhase 2NCT04845178 · Started September 4, 2024 · AEON Biopharma, Inc.

Migraine DisordersHeadache Disorders, PrimaryABP-450

A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years (opens in a new tab)

CompletedPhase 1/2NCT05266456 · Started April 18, 2024 · Vaxcyte, Inc.

20 valent pneumococcal conjugate vaccine24 valent pneumococcal conjugate vaccine

A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee (opens in a new tab)

CompletedPhase 3NCT03081806 · Started March 28, 2024 · Techfields Pharma Co. Ltd

OsteoarthritisRheumatic DiseasesX0002

A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above (opens in a new tab)

Active, not recruitingPhase 3NCT04732871 · Started December 21, 2023 · GlaxoSmithKline

Pneumovirus InfectionsRespiratory Syncytial Virus InfectionsRSVPreF3 OA investigational vaccine

See all 12 clinical trials and co-investigators

Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)

Dr. John E. Ervin received $9,671 in industry payments from 2017 to 2022

CMS Open Payments shows 14 general payments to Dr. Ervin from 3 drug and device companies from 2017 to 2022. Travel and lodging make up the largest share, 95% of the total. Sanofi and Genzyme US Companies paid the most, $7,460. It also lists 32 research payments totaling $143,103 from 2016 to 2023, naming 2 clinical trials.

General payments to Dr. Ervin by program year, 2017 to 2022

General payments to Dr. Ervin by kind, 2017 to 2022

$9.7Kin total

Travel and lodging$9,22095%
Food and beverage$4525%

Companies that paid Dr. Ervin the most, 2017 to 2022

Share is of all general payments to this clinician.

See all payments to Dr. Ervin

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Sources for Dr. John E. Ervin's profile data

Sources for the data on this page
Data on this page	Source
NPI, name, sex, specialty and licenses	NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phone	Dmand AI Affiliation Data
Primary practice, affiliations and health system	Dmand AI Affiliation Data
Part D prescribing	Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)
Publications, topics and co-authors	PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Clinical trials and co-investigators	Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab)
Industry payments	Open Payments (CMS) (opens in a new tab)
EHR at each practice site	Dmand AI Technology Install Data
Similar physicians	Dmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracy Remove my information

FAQ

Frequently asked questions about Dr. John E. Ervin

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. John E. Ervin's NPI number?

Dr. John E. Ervin's NPI number is 1376565549. It was assigned on July 24, 2006, and it is active in the NPI Registry.

What kind of doctor is Dr. John E. Ervin?

Dr. John E. Ervin is a rheumatologist in Kansas City, Missouri. The primary specialty in the NPI Registry is Rheumatology Physician (taxonomy code 207RR0500X).

Where does Dr. John E. Ervin practice?

Dr. Ervin practices at 1010 Carondelet Dr Suite 426 Suite 426, Kansas City, MO 64114. Dr. Ervin's primary practice is AMR Clinical Kansas City in Kansas City, Missouri.

What is Dr. John E. Ervin's office phone number?

The practice phone on file for Dr. Ervin is (816) 943-1292.

What is Dr. John E. Ervin's medical license number?

Dr. Ervin holds Missouri license R7363.

What drugs does Dr. John E. Ervin prescribe most?

In 2019 Medicare Part D data, Dr. Ervin's most prescribed drugs by claims were Amoxicillin-Clavulanate Potass.

Has Dr. John E. Ervin received payments from drug or device companies?

CMS Open Payments shows $9,671 in general payments to Dr. Ervin from 3 companies from 2017 to 2022. The largest total came from Sanofi and Genzyme US Companies.

How long has Dr. John E. Ervin been practicing?

Dr. Ervin's NPI was assigned in 2006.

Does Dr. John E. Ervin do research?

Dmand AI links 19 publications to Dr. Ervin, published from 2011 to 2024. Dr. Ervin has worked on 12 clinical trials.

Who does Dr. John E. Ervin publish with?

Dr. Ervin's most frequent co-authors are Ann R. Falsey, MD (2 shared papers), Alan J. Kivitz, MD (2 shared papers) and Seth Mitchell Lieberman, MD (2 shared papers).

Selling to rheumatology practices?

See rheumatologists in Missouri by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

Start free trial Book a demo

30 days free
Self-serve
No credit card